The EPO granted patent EP4294441A1 covering anti-claudin 18.2 (Cldn18.2) antibody conjugates for cancer treatment. Inventors include Qian Xueming, Zhu Hua, Teng Fei, and others from Transcenta Therapeutics and Beijing Cancer Hospital. The patent specifies Cldn18.2 as a target for antibody-drug conjugates (ADCs) effective against multiple cancer types including gastric, pancreatic, esophageal, lung, and ovarian cancers.

Patent holders and licensees should review the granted claims for freedom-to-operate considerations. Pharmaceutical companies developing ADC-based oncology therapeutics targeting Cldn18.2 should assess potential licensing requirements. No compliance deadlines apply to this patent publication as it represents an intellectual property grant rather than a regulatory requirement.